ZYDUSLIFE

- Entered into a strategic partnership with Bioeq, a Swiss biopharmaceutical company,

- Entered into a strategic partnership with Bioeq, a Swiss biopharmaceutical company, The company’s subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates, has entered into a strategic partnership with Bioeq, a Swiss biopharmaceutical company, for the licensing, supply, and commercialization of Bioeq’s Vascular Endothelial Growth Factor (VEGF) inhibitor, Nufymco—an interchangeable biosimilar of Lucentis (Ranibizumab)—for the US market. The Biologics License Application (BLA) for Nufymco was approved by the US Food and Drug Administration (USFDA) on December 18. All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24